{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:59:38Z","timestamp":1790805578719,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.xphs.2026.104437","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T06:45:35Z","timestamp":1784961935000},"page":"104437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Formulation development and evaluation of nasal in situ gel of promethazine hydrochloride- part II: Pharmacokinetic evaluation and bioavailability studies"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8709-7778","authenticated-orcid":false,"given":"Surabhi H.","family":"Patil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8562-8670","authenticated-orcid":false,"given":"Sanjay B.","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2026.104437_bib0001","series-title":"Martindale the Complete Drug Reference","first-page":"615","author":"Sweetman","year":"2011"},{"issue":"2","key":"10.1016\/j.xphs.2026.104437_bib0002","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/09687860600945628","article-title":"Microcapsule-gel formulation of promethazine HCl for controlled nasal delivery: a motion sickness medication","volume":"24","author":"McDonough","year":"2007","journal-title":"J Microencapsul"},{"issue":"4","key":"10.1016\/j.xphs.2026.104437_bib0003","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/03639040600920309","article-title":"Development and in vitro characterization of chitosan-based microspheres for nasal delivery of promethazine","volume":"33","author":"Hafner","year":"2007","journal-title":"Drug Dev Ind Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2026.104437_bib0004","first-page":"276","article-title":"Formulation and characterization of mucoadhesive microspheres of promethazine for nasal delivery","volume":"4","author":"Illiger","year":"2011","journal-title":"J Pharm Res"},{"key":"10.1016\/j.xphs.2026.104437_bib0005","doi-asserted-by":"crossref","DOI":"10.1006\/phrs.1998.0328","article-title":"Bioavailability of intranasal promethazine dosage forms in dogs","volume":"38","author":"Ramanathan","year":"1998","journal-title":"Pharmacol Res"},{"issue":"2-s","key":"10.1016\/j.xphs.2026.104437_bib0006","doi-asserted-by":"crossref","first-page":"183","DOI":"10.22270\/jddt.v10i2-s.4029","article-title":"Nasal in situ gel: novel approach for nasal drug delivery","volume":"10","author":"Sabale","year":"2020","journal-title":"J Drug Deliv Ther"},{"key":"10.1016\/j.xphs.2026.104437_bib0007","series-title":"Situ Gels for Nasal Delivery: Formulation, Characterization and Applications. Macromolecular Materials and Engineering","author":"Qian","year":"2025"},{"key":"10.1016\/j.xphs.2026.104437_bib0008","first-page":"179","article-title":"Drug delivery to the brain: in situ gelling formulation enhances carbamazepine diffusion through nasal mucosa models with mucin","author":"Corazza","year":"2022","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2026.104437_bib0009","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/03639045.2023.2291463","article-title":"Formulation development and evaluation of nasal in situ gel of promethazine hydrochloride","volume":"50","author":"Boraste","year":"2023","journal-title":"Drug Dev Ind Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2026.104437_bib0010","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3109\/10717544.2013.849778","article-title":"Development of in situ gel for nasal delivery: design, optimization, in vitro and in vivo evaluation","volume":"21","author":"Galgatte","year":"2014","journal-title":"Drug Deliv"},{"key":"10.1016\/j.xphs.2026.104437_bib0011","unstructured":"International Conference on Harmonization of Technical Requirements for registration of pharmaceuticals for human use ICH harmonized tripartite guideline stability testing of new drug substances and products Q1A(R2). 2003."},{"issue":"5","key":"10.1016\/j.xphs.2026.104437_bib0012","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3109\/10717544.2012.704095","article-title":"Thermally reversible xyloglucan gels as vehicles for nasal drug delivery","volume":"19","author":"Mahajan","year":"2012","journal-title":"Drug Deliv"},{"issue":"1","key":"10.1016\/j.xphs.2026.104437_bib0013","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3109\/10717540903447194","article-title":"In situ gels of metoclopramide hydrochloride for intranasal 4delivery: in vitro evaluation and in vivo pharmacokinetic study in rabbits","volume":"17","author":"Mahajan","year":"2010","journal-title":"Drug Deliv"},{"issue":"4\u20135","key":"10.1016\/j.xphs.2026.104437_bib0014","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ejps.2007.08.006","article-title":"Abd ElHady SS. Enhanced bioavailability of metoclopramide HCl by intranasal administration of a mucoadhesive in situ gel with modulated rheological and mucociliary transport properties","volume":"32","author":"Zaki","year":"2007","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"10.1016\/j.xphs.2026.104437_bib0015","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.2042-7158.1983.tb02935.x","article-title":"Determinants of systemic availability of promethazine in rabbits","volume":"35","author":"Taylor","year":"1983","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.xphs.2026.104437_bib0016","unstructured":"Pharmacokinetic study of promethazine in Korean healthy subjects using a validated HPLC method."},{"key":"10.1016\/j.xphs.2026.104437_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/0378-5173(81)90039-9","article-title":"Absorption rate and bioavailability of promethazine from rectal and oral dosage forms","volume":"9","author":"Moolenaar","year":"1981","journal-title":"Int J Pharm"},{"issue":"14","key":"10.1016\/j.xphs.2026.104437_bib0018","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1080\/00032717908082544","article-title":"Determination of promethazine in biological fluids","volume":"12","author":"Taylor","year":"1979","journal-title":"Anal Lett"},{"key":"10.1016\/j.xphs.2026.104437_bib0019","doi-asserted-by":"crossref","DOI":"10.1006\/phrs.1998.0328","article-title":"Bioavailability of intranasal promethazine dosage forms in dogs","volume":"38","author":"Ramanathan","year":"1998","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.xphs.2026.104437_bib0020","unstructured":"High-pressure liquid chromatographic determination of PMZ."},{"key":"10.1016\/j.xphs.2026.104437_bib0021","doi-asserted-by":"crossref","unstructured":"Strenkoski-Nix LC, Ermer J, Decleene S, Cevallos W, Mayer PR. REPORT promethazine hydrochloride pharmacokinetics of promethazine hydrochloride after administration of rectal suppositories and oral syrup to healthy subjects [Internet]. Am J Health-Syst Pharm. Available from: https:\/\/academic.oup.com\/ajhp\/article-abstract\/57\/16\/1499\/5151060","DOI":"10.1093\/ajhp\/57.16.1499"},{"key":"10.1016\/j.xphs.2026.104437_bib0022","first-page":"1","article-title":"Recent advances in the development of in situ gelling drug delivery systems for non-parenteral administration routes","volume":"12","author":"Vigani","year":"2020"},{"issue":"7","key":"10.1016\/j.xphs.2026.104437_bib0023","doi-asserted-by":"crossref","first-page":"806","DOI":"10.3109\/03639040903517906","article-title":"Ondansetron-loaded chitosan microspheres for nasal antiemetic drug delivery: an alternative approach to oral and parenteral routes","volume":"36","author":"Gungor","year":"2010","journal-title":"Drug Dev Ind Pharm"},{"issue":"6","key":"10.1016\/j.xphs.2026.104437_bib0024","doi-asserted-by":"crossref","DOI":"10.3390\/gels8060342","article-title":"Intranasal delivery of darunavir-loaded mucoadhesive in situ gel: experimental design, in vitro evaluation, and pharmacokinetic studies","volume":"8","author":"Nair","year":"2022","journal-title":"Gels"},{"key":"10.1016\/j.xphs.2026.104437_bib0025","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jddst.2019.01.040","article-title":"Resveratrol anchored nanostructured lipid carrier loaded in situ gel via nasal route: formulation, optimization and in vivo characterization","volume":"51","author":"Rajput","year":"2019","journal-title":"J Drug Deliv Sci Technol"},{"issue":"3","key":"10.1016\/j.xphs.2026.104437_bib0026","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s13346-020-00800-w","article-title":"Piribedil loaded thermo-responsive nasal in situ gelling system for enhanced delivery to the brain: formulation optimization, physical characterization, and in vitro and in vivo evaluation","volume":"11","author":"Uppuluri","year":"2021","journal-title":"Drug Deliv Transl Res"},{"issue":"2","key":"10.1016\/j.xphs.2026.104437_bib0027","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40005-020-00505-9","article-title":"Thermosensitive nasal in situ gelling systems of rufinamide formulated using modified tamarind seed xyloglucan for direct nose-to-brain delivery: design, physical characterization, and in vivo evaluation","volume":"51","author":"Dalvi","year":"2021","journal-title":"J Pharm Investig"},{"issue":"1","key":"10.1016\/j.xphs.2026.104437_bib0028","doi-asserted-by":"crossref","DOI":"10.3390\/scipharm90010008","article-title":"Pharmacokinetic study of mucoadhesive itopride hydrochloride in situ nasal gel formulations in a comparative in vivo study and histopathological safety evaluation","volume":"90","author":"Marzouk","year":"2022","journal-title":"Sci Pharm"},{"issue":"7","key":"10.1016\/j.xphs.2026.104437_bib0029","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-019-1513-x","article-title":"A nasal temperature and pH dual-responsive in situ gel delivery system based on microemulsion of huperzine a: formulation, evaluation, and in vivo pharmacokinetic study","volume":"20","author":"Chen","year":"2019","journal-title":"AAPS PharmSciTech"},{"issue":"4","key":"10.1016\/j.xphs.2026.104437_bib0030","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1080\/1061186X.2024.2433557","article-title":"Development of in vitro and in vivo evaluation of mucoadhesive in-situ gel for intranasal delivery of vinpocetine","volume":"33","author":"Hard","year":"2024","journal-title":"J Drug Target"},{"issue":"3","key":"10.1016\/j.xphs.2026.104437_bib0031","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-018-1211-0","article-title":"Buspirone hydrochloride loaded in situ nanovesicular gel as an anxiolytic nasal drug delivery system: in vitro and animal studies","volume":"20","author":"Abdelnabi","year":"2019","journal-title":"AAPS PharmSciTech"},{"issue":"21","key":"10.1016\/j.xphs.2026.104437_bib0032","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27217644","article-title":"Preparation, in vitro and in vivo evaluation of nanoemulsion in situ gel for transnasal delivery of traditional Chinese medicine volatile oil from Ligusticum sinense Oliv.cv. Chaxiong","volume":"27","author":"Huang","year":"2022","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.xphs.2026.104437_bib0033","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-021-02020-y","article-title":"Intranasal in situ gel of apixaban-loaded nanoethosomes: preparation, optimization, and in vivo evaluation","volume":"22","author":"El-Shenawy","year":"2021","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.xphs.2026.104437_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1577331","article-title":"Escitalopram oxalate-loaded chitosan nanoparticle in situ gel formulation intended for direct nose-to-brain delivery: in vitro, ex vivo, and in vivo pharmacokinetic evaluation","volume":"16","author":"Mujtaba","year":"2025","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.xphs.2026.104437_bib0035","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13081216","article-title":"Ion-triggered in situ gelling nanoemulgel as a platform for nose-to-brain delivery of small lipophilic molecules","volume":"13","author":"Nagaraja","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xphs.2026.104437_bib0036","doi-asserted-by":"crossref","first-page":"10435","DOI":"10.2147\/IJN.S265659","article-title":"Nose-to-brain delivery by nanosuspensions-based in situ gel for breviscapine","volume":"15","author":"Chen","year":"2020","journal-title":"Int J Nanomed"},{"issue":"2","key":"10.1016\/j.xphs.2026.104437_bib0037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5530\/ijper.58.2.41","article-title":"Nasal administration of dolutegravir loaded nanoparticles based mucoadhesive in situ gel: design and in vivo assessment","volume":"58","author":"Sreeharsha","year":"2024","journal-title":"Indian J Pharm Educ Res"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926002868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926002868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:26:07Z","timestamp":1790803567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926002868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0022354926002868"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104437","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Formulation development and evaluation of nasal in situ gel of promethazine hydrochloride- part II: Pharmacokinetic evaluation and bioavailability studies","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104437","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104437"}}